KW-6356 is a follow-up to Kyowa Kirin's first-generation adenosine A2 antagonist Nourianz/Nouriast (istradefylline), which finally claimed FDA approval in 2019 as an add-on to levodopa in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...